Patent intelligence · US
US 12329748
Anhydrous compositions of mTOR inhibitors and methods of use
Anhydrous compositions of mTOR inhibitors and methods of use
Patent details — US 12329748
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 17, 2025
- Expiration
- Jun 12, 2045
- Applicant
- PALVELLA THERAPEUTICS, INC.
- Claims
- 51
- CPC classes
- A61K, A61K31/436, A61K31/5377, A61K45/06
Quick answer
US 12329748 (Anhydrous compositions of mTOR inhibitors and methods of use) is held by PALVELLA THERAPEUTICS, INC.. Status: granted. Granted Jun 17, 2025. Expires Jun 12, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PALVELLA THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 51
- CPC classes
- A61K, A61K31/436, A61K31/5377, A61K45/06, A61K47/10, A61K47/14
More from PALVELLA THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12268673
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 11679101
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 11617742
Methods of treating keratin hyperproliferation disorders using mTOR inhibitors
granted -
US 11135204
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 11000513
Anhydrous compositions of mTOR inhibitors and methods of use
granted -
US 10722499
Anyhydrous compositions of mTOR inhibitors and methods of use
granted -
US 10172789
Compositions for transdermal delivery of mTOR inhibitors
granted
Frequently asked questions
What is US patent 12329748?
US 12329748 (Anhydrous compositions of mTOR inhibitors and methods of use) is held by PALVELLA THERAPEUTICS, INC.. Status: granted. Granted Jun 17, 2025. Expires Jun 12, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12329748?
PALVELLA THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 12329748 expire?
Our index shows an expiration date of Jun 12, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.